MannKind Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MannKind stock.
View analyst ratings for MannKind or view top-rated stocks.

Wall Street analysts have given MannKind a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MannKind wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for MannKind.

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings results on Wednesday, November, 4th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.01. The biopharmaceutical company had revenue of $15.35 million for the quarter, compared to analysts' expectations of $15.74 million.
View MannKind's earnings history.

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MNKD shares have increased by 233.6% and is now trading at $3.67.
View which stocks have been most impacted by COVID-19.

5 analysts have issued 1 year price targets for MannKind's stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate MannKind's share price to reach $6.63 in the next year. This suggests a possible upside of 80.5% from the stock's current price.
View analysts' price targets for MannKind or view top-rated stocks among Wall Street analysts.

Some companies that are related to MannKind include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
View all of MNKD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

MannKind's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.73%), Avoro Capital Advisors LLC (1.50%), Northern Trust Corp (1.09%), Charles Schwab Investment Management Inc. (0.64%), Nuveen Asset Management LLC (0.55%) and Morgan Stanley (0.51%). Company insiders that own MannKind stock include Alejandro Galindo, Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross.
View institutional ownership trends for MannKind.

MNKD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, Beirne Wealth Consulting Services LLC, GSA Capital Partners LLP, Sowell Financial Services LLC, Wells Fargo & Company MN, Northern Trust Corp, and Dupont Capital Management Corp.
View insider buying and selling activity for MannKind or view top insider-selling stocks.

MNKD stock was purchased by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, Nuveen Asset Management LLC, BlackRock Inc., Credit Suisse AG, ClariVest Asset Management LLC, 180 Wealth Advisors LLC, BBR Partners LLC, and Squarepoint Ops LLC. Company insiders that have bought MannKind stock in the last two years include Alejandro Galindo, Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder, and Stuart A Tross.
View insider buying and selling activity for MannKind or or view top insider-buying stocks.

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MNKD stock can currently be purchased for approximately $3.67.

MannKind has a market capitalization of $907.07 million and generates $63.04 million in revenue each year. The biopharmaceutical company earns $-51,900,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

MannKind employs 232 workers across the globe.

The official website for MannKind is www.mannkindcorp.com.

MannKind is headquartered at 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362.

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]